Less than a week after the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) approved Leo Pharma's drug tralokinumab, the US Food and Drug Administration (FDA) has arrived at the opposite conclusion in the form of a complete response letter.
In the letter, the FDA calls for further data concerning the device component of tralokinumab that is the injection pen which holds the drug, according to a Leo Pharma press release.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.